TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01358084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Study: NCT01908205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01230645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV568
Description: RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
Study: NCT02734524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: Natural killer cell infusion is an intervention between two arms. Dosage of infused cell \>1×10\^9，q28d\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 135-175mg/m2,q28d\*4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxol
Description: 135-175mg/m2,q28d\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5,q28d\*4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=5,q28d\*4
Study: NCT01501968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Colistimethate sodium 2.5-5mg/kg iv per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin + Ascorbic acid
Description: Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
Study: NCT01402973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
Study: NCT05044494

Intervention type: PROCEDURE
Intervention: non-prompt surgery
Study: NCT01594034

Intervention type: PROCEDURE
Intervention: expired air
Description: collection of expired air from ventilator
Study: NCT02020967

Intervention type: OTHER
Intervention: Non-interventional cross-sectional survey
Description: This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
Study: NCT01311427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-form Yang-style Tai chi
Description: This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group education
Description: Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
Study: NCT03259789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin tablets, 20 mg
Description: Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bexagliflozin tablets, placebo
Description: Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexagliflozin tablets, 20 mg
Description: Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
Study: NCT02523794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-kinetically Modified Water
Description: Subjects assigned to this arm will receive the EMW

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Purified Drinking Water
Study: NCT01448148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Description: Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
Study: NCT02121418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02343744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary.
Study: NCT03906630

Intervention type: DIAGNOSTIC_TEST
Intervention: Telehealth clinical exam
Description: This is a pseudo telehealth clinical exam for patients presenting with shoulder pain

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard clinical exam
Description: This is a standard in-person clinical exam for patients presenting with shoulder pain
Study: NCT02503202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Consistency Lot A
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Consistency Lot B
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 Consistency Lot C
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920 High-dose Lot
Description: V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to V920
Description: Sodium chloride 0.9%, sterile solution for intramuscular injection
Study: NCT03691961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair sampling
Description: After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair sampling
Description: After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hair's drug concentrations
Description: The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hair's drug concentrations
Description: The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
Study: NCT02586454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Study: NCT02078011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
Study: NCT03581968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: The system is composed of 3 main components:~1. Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~2. Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~3. MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump.
Study: NCT00454792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Back exercise: At home every day. In groups once a week. Duration 10 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restitution
Description: Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
Study: NCT01664104

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
Study: NCT02540642

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: METHYLCOBALAMIN 500 micrograms
Description: Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
Study: NCT03586167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LID014341 contact lenses
Description: Investigational monthly replacement silicone hydrogel contact lenses with water gradient coating

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Silicone hydrogel contact lenses
Study: NCT04245319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acitretin
Description: The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B
Description: Patients receive nbUVB session 3 times per week

Intervention type: OTHER
Group type: OTHER
Intervention: Narrow band ultraviolet B
Description: Patients receive nbUVB session 3 times per week
Study: NCT03213470

Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging
Study: NCT02795650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalised treatment
Description: Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment chosen per investigator´s judge
Description: Investigators are allowed to chose what they consider the best standard treatment option for their patients.
Study: NCT03673709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antenatal Care
Description: Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
Study: NCT01571037

Intervention type: DRUG
Group type: OTHER
Intervention: inhaled nebulized milrinone
Description: 0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
Study: NCT04363086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iFightDepression online self-help tool
Description: Computerized cognitive behavior therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iFightDepression online self-help tool
Description: Computerized cognitive behavior therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: TAU
Study: NCT02633501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Single IV bolus injection at a rate of 2 mL/second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Single IV bolus injection at a rate of 2 mL/second

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT04363086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone call
Description: phone call
Study: NCT02633501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT01488305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP (micro-nutrient powders)
Description: MNP is added to explore the additional value of MNP in existing AAMA program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAMA project activities (HFP and IYCF BCC)
Description: This is the existing AAMA program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAMA project activities (HFP and IYCF BCC)
Description: This is the existing AAMA program
Study: NCT01235624

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis
Study: NCT02839967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation placebo
Description: The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
Study: NCT04413240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: * VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~* K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~* Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
Study: NCT01125176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 50 mg oral dosing every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: varying oral doses every other day (max 25 mg/day)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
Study: NCT03796156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75mg low dose non enteric coated or dispersible
Study: NCT02648035

Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: Subcutaneous Tocilizumab according to approved label.
Study: NCT04152005

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease

Intervention type: OTHER
Intervention: Observation
Description: Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
Study: NCT03544671

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study: NCT03781882

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma infiltration in the wound edges
Description: platelet rich plasma will be injected in the wound edges

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of wound without platelet rich plasma infiltration
Description: No infiltration of platelet rich plasma is done
Study: NCT00237796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Description: Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal Focused Supportive Contact (GFSC)
Description: Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
Study: NCT00549237

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose load (Nutricia)
Description: Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post operative early enteral feeding
Description: Enteral feeding starting 6 hours post surgery
Study: NCT03581773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: 5 mg pr day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 1 placebo pill pr day for 12 weeks